

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior listings.

Claims 1-36 (cancelled)

37 (new): A composition comprising:

N-[(3R,5S)-1-(3-Acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid, or a salt thereof; and

one or more agents for controlling the biosynthesis of cholesterol.

38 (new): A composition as claimed in claim 37 further comprising a pharmaceutically acceptable carrier.

39 (new): A composition as claimed in claim 37 wherein the one or more agents for controlling the biosynthesis of cholesterol are HMG-CoA reductase inhibiting agents.

40 (new): A composition as claimed in claim 39 wherein the HMG-CoA reductase inhibiting agent is a statin.

41 (new): A composition as claimed in claim 39 wherein the HMG-CoA reductase inhibiting agent is selected from the group consisting of lovastatin, simvastatin and pravastatin.

42 (new): A composition comprising:

N-[(3R,5S)-1-(3-Acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid, or a salt thereof;

one or more agents for controlling the biosynthesis of cholesterol selected from the group consisting of lovastatin, simvastatin and pravastatin; and

a pharmaceutically acceptable carrier.

43 (new): A method for preparation of a pharmaceutical composition comprising admixing the composition of claim 37 with a pharmaceutically acceptable carrier.

44 (new): A method for prophylaxis or therapy of hyperlipidemia in a mammal comprising administering an effective amount of N-[(3R,5S)-1-(3-Actoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid, or a salt thereof, in combination with one or more agents for controlling the biosynthesis of cholesterol in said mammal.

45 (new): A method for lowering the lipid-level in a mammal comprising administering an effective amount of N-[(3R,5S)-1-(3-Actoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid, or a salt thereof, in combination with one or more agents for controlling the biosynthesis of cholesterol in said mammal.

46 (new): A method for lowering the level of triglyceride in a mammal comprising administering an effective amount of N-[(3R,5S)-1-(3-Actoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid, or a salt thereof, in combination with one or more agents for controlling the biosynthesis of cholesterol in said mammal.

47 (new): The method of any one of claims 44, 45 or 46 wherein the one or more agents for controlling the biosynthesis of cholesterol in said mammal are HMG-CoA reductase inhibiting agents.

48 (new): The method of claim 47 wherein the HMG-CoA reductase inhibiting agent is a statin.

49 (new): The method of claim 47 wherein the HMG-CoA reductase inhibiting

agents are selected from the group consisting of lovastatin, simvastatin and pravastatin.

50 (new): A method for controlling the biosynthesis of cholesterol in a mammal comprising administering an effective amount of N-[(3R,5S)-1-(3-Acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetyl]piperidine-4-acetic acid, or a salt thereof, in combination with one or more agents selected from the group consisting of lovastatin, simvastatin and pravastatin.